ETNB Stock Summary and Trading Ideas (89Bio | NASDAQ:ETNB)

89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

89Bio trades on the NASDAQ stock market under the symbol ETNB.

As of April 19, 2024, ETNB stock price climbed to $9.08 with 922,365 million shares trading.

ETNB has a beta of 1.41, meaning it tends to be more sensitive to market movements. ETNB has a correlation of 0.03 to the broad based SPY ETF.

ETNB has a market cap of $864.64 million. This is considered a Small Cap stock.

In the last 3 years, ETNB stock traded as high as $28.28 and as low as $2.00.

The top ETF exchange traded funds that ETNB belongs to (by Net Assets): XBI, VTI, IWM, VXF, IWO.

ETNB has underperformed the market in the last year with a price return of -46.8% while the SPY ETF gained +21.2%. ETNB has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -18.1% and -14.7%, respectively, while the SPY returned +4.3% and -3.5%, respectively.

ETNB support price is $8.58 and resistance is $9.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ETNB stock will trade within this expected range on the day.